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Imaging characterization
of non-hypersecreting adrenal masses:
comparison between MR and radionuclide techniques
S. MAUREA 1, C. CARACÒ 2, M. KLAIN 1, C. MAINOLFI 1, M. SALVATORE 1
Aim. In patients with non-hypersecreting adrenal mass-
es, tumor characterization is clinically relevant to estab-
lish the appropriate treatment planning. The aim of this
study was to comparatively characterize such adrenal
lesions using MR and radionuclide techniques.
Methods. Thirty patients with non-hypersecreting uni-
lateral adrenal tumors underwent both MR and adren-
al scintigraphy. MR was performed using SE T1- (pre- and
post-gadolinium DTPA) and T2-weighted images as well
as in- and out-phase chemical-shift imaging (CSI). MR
qualitative and quantitative (signal intensity ratios) eval-
uation was performed. Radionuclide studies consisted of
iodine-131 nor-cholesterol (n=20), iodine-131 MIBG
(n=15) and fluorine-18 FDG PET (n=11) scans. Histology
(n=16), biopsy (n=3) or clinical-imaging follow-up (n=11)
demomstrated 13 adenomas, 3 cysts, 2 myelolipomas, 4
pheochromocytomas (pheos), 4 carcinomas, 1 sarco-
ma and 3 metastases. Comparative imaging analysis was
focused on adenomas, pheos and malignant tumors.
Results. Qualitative MR evaluation showed: signal T2-
hyperintensity in 46% of adenomas and in 100% of phe-
os and malignant tumours, no gadolinium enhance-
ment in 92% of adenomas and definite signal intensity
loss on CSI in 100% of such tumour lesions, gadolin-
ium enhancement in 100% of pheos and in 63% of malig-
nancies and no absolute change of signal intensity on CSI
in 100% of both pheos and malignancies. Quantitative
MR analysis demonstrated: significantly higher signal T2-
hyperintensity of pheos compared to adenomas and
malignancies as well as significantly higher enhance-
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ment after gadolinium in pheos compared to adenomas
and malignancies (p<0.03). Radionuclide studies showed
significantly increased nor-cholesterol uptake only in
adenomas (n=13), significant MIBG accumulation only
in pheos (n=4) and FDG activity only in malignant adren-
al lesions (n=8). Conclusion. MR techniques may pro-
vide some presumptive criteria to characterize non-
hypersecreting adrenal masses, such as no gadolinium
enhancement and definite signal intensity loss on CSI in
adenomas or quantitatively measured T2-hyperinten-
sity and gadolinium enhancement in pheos. On the oth-
er hand, radionuclide modalities offer more specific
findings in this setting since nor-cholesterol and MIBG
scans are respectively able to reveal benign tumours
such as adenoma and pheochromocytoma, while FDG
imaging allows identification of malignant adrenal
lesions. Adrenal scintigraphy is recommended in those
patients, when MR images are uncertain or inconclu-
sive.
KEY WORDS: Glands - Neoplasms - Magnetic resonance imag-
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The high resolution of anatomic imaging tech-niques such as computed tomography (CT) and
magnetic resonance (MR), used in patients with sus-
pected abdominal diseases, frequently results in
detection of unexpected adrenal masses.1, 2 In this set-
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ting, the main clinical question consists of differen-
tial diagnosis between benign and malignant adren-
al lesions in order to select appropriate treatment.2
As initial diagnostic approach, clinical and laborato-
ry assessment of cortical and medullary adrenal func-
tion allow the identification of hypersecreting adren-
al lesions and, hence, characterization of these
tumours.3 A tumour mass, however, may not cause
adrenal hyperfunction since it may be non-hyper-
secreting or secretes non-active products. In such
conditions, lesion typing remains uncertain. CT and
MR accurately provide anatomic details of adrenal
tumours as well as presumptive criteria for diagno-
sis.4 In particular, adrenal adenomas may be sug-
gested by CT on the basis of low attenuation coeffi-
cient on un-enhanced images and/or early as well as
rapid washout on enhanced scans.5 Similarly, MR is
able to characterize adenomas using chemical-shift
sequence or pheochromocytomas showing clearly
increased signal intensity on T2-weighted images
and significant enhancement after gadolinium admin-
istration.6
In patients with non-hypersecreting adrenal mass-
es, radionuclide adrenal imaging performed with
specifically labelled radiopharmaceuticals which tar-
get elements of adrenal function provide specific
metabolic information for diagnosis, thus, comple-
menting morphological imaging modalities.7, 8 In
particular, a diagnostic role of molecular imaging
has been identified in the management of patients
with non-hypersecreting adrenal masses.9 In this
regard, several radiotracers which display unique
biological behaviour may be used in nuclear medi-
cine for adrenal lesion evaluation. These include
tracers labelled with single photon emitters 7, 10 such
as radio-iodine labelled nor-cholesterol and meta-
iodobenzylguanidine (MIBG) and gallium-67 cit-
rate.11 Alternatively there are agents labelled with
positron emitters such as hydroxy-ephedrine,12
deoxy-glucose 13-15 and metomidate.16 Finally, radio-
labeled somatostatin analogs have been proposed
to identify somatostatin receptors in malignant adren-
al tumours.17
In this study, we compared the results of MR imag-
ing techniques and those of radionuclide studies in
patients with non-hypersecreting adrenal masses in
order to evaluate imaging criteria for accurately per-
forming non-invasive preoperative tumour character-
ization and, hence, to differentiate benign from malig-
nant lesions. 
Materials and methods
Patient population
Thirty patients (10 male and 20 female, mean age
51±13 years) with non-hypersecreting unilateral adren-
al masses (tumour size=4.6±3.0 cm) detected on ultra-
sound and/or CT studies underwent both MR imaging
and adrenal scintigraphy using appropriate radiophar-
maceuticals. The selection criteria for patient enroll-
ment consisted of the presence of non-hypersecreting
adrenal tumours discovered in subjects who had diag-
nostic evaluation of non-adrenal disorders: abdominal
pain (n=7), abdominal trauma (n=3), biliary tract stone
disease (n=3), renal cysts (n=4), anuria (n=3) or dur-
ing the staging (n=5) or follow-up (n=5) for malignant
tumours. No patient showed signs and/or symptoms
of adrenal hyper-secretion. A total of 46 adrenal radio-
nuclide studies was analyzed consisting of iodine-
131 nor-cholesterol scintigraphy (n=20), iodine-131
MIBG imaging (n=15) and fluorine-18 deoxyglucose
(FDG) positron emission tomography (PET) (n=11).
Histology (n=16), biopsy (n=3) or 2-years clinical-
imaging follow-up (n=11) were used as standard of ref-
erence demonstrating a total of 22 benign adrenal
lesions, of which 13 were adenomas, 3 were cysts, 2
were myelolipomas and 4 were pheochromocytomas
(pheos), as well as a total of 8 malignant tumours, of
which 4 were carcinomas, 1 was a sarcoma and 3
had metastases. Informed consent, as required by the
Institutional Clinical Research Sub-panel on Human
Studies at our Institute, was obtained in all patients. 
Laboratory analysis
In all patients, the evaluation of adrenal function
consisted of screening tests for excess of mineral-
corticoid, glucocorticoid, androgen and catechola-
mine secretion. In particular, measurement of plas-
ma aldosterone levels and renin activity in clinostat-
ic as well as orthostatic posture was performed.
Plasma cortisol and corticotropin levels were meas-
ured at 8:00 a.m. and 11:00 p.m. and a 24-hour urine
assay for free cortisol was performed. Measurements
of serum dehydroepiandrosterone sulfate, 17-hydrox-
yprogesterone, androstenedione, testosterone and
electrolyte levels were included. An overnight low-
dose dexamethasone (DS) suppression test (1 mg
orally at 11:00 p.m. and measurement of serum cor-
tisol level at 8:00 a.m. the following morning) was
also performed. For the evaluation of medullary
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adrenal function, plasma catecholamine levels, 24-
hour urinary excretions of catecholamines and their
metabolites, vanillylmandelic acid and metaneph-
rine, were measured. Hormonal values were deter-
mined by radioimmunoassay or immunoradiomet-
ric assay methods using commercially available kits.
Urinary catecholamine, vanillylmandelic acid and
metanephrine levels were measured by high-perfor-
mance liquid chromatography. Sodium and potas-
sium levels were assessed by flame photometry with
lithium as an internal standard. 
Magnetic resonance
MR imaging studies were performed with a 1.5
Tesla superconducting magnet scanner (Magnetom,
Siemens, Erlangen, Germany). A spin echo technique
was used to obtain 5 mm contiguous 3-dimensional
sections of the abdomen. T1-weighted images
(TR/TE=600/15 ms) and T2-weighted images (TR/TE=
2000/15-90 ms) were obtained. T1-weighted images
were also acquired after the intravenous administra-
tion of gadolinium-DTPA (0.2 ml/kg of weight body,
Magnevist, Schering). MR imaging studies were also
integrated using chemical-shift (CS) sequence acquir-
ing in-phase and out-of-phase images (TR/TE=100/6-
4 ms). 
Nor-cholesterol imaging
Before nor-cholesterol injection, thyroid iodine
uptake was blocked with a saturated solution of potas-
sium iodide (200 mg per day orally, starting the day
before tracer administration and continuing for 8
days). Iodine-131 nor-cholesterol (37 MBq, CIS Bio
International, Cedex, France) was injected intrave-
nously. Adrenal scintigraphy was performed 5 (early)
and 7 (delayed) days after tracer injection using a
large field of view γ camera (Orbiter, Siemens,
Erlangen, Germany) with a high-energy collimator
and a 20% window centered at 364 Kev. Early and
delayed posterior abdominal views were acquired. A
mild laxative (bisacodyl) was given (10 mg) twice
daily beginning 2 days before the 1st day of imaging
to reduce interfering colonic iodine-131 activity. When
required, norcholesterol adrenal scintigraphy was also
performed with a concomitant DS suppression test. For
this, 1 mg of DS was administered 4 times daily for 7
days prior to nor-cholesterol and for 5 days after trac-
er injection.
MIBG imaging
Before MIBG injection, thyroid iodine uptake was
blocked with a saturated solution of potassium iodide
(200 mg per day orally, starting before tracer admin-
istration and continuing for 8 days). Iodine-131 MIBG
(37 MBq, Amersham Sorin, Saluggia, Italy) was
administered intravenously. Posterior abdominal spot
views were obtained at 24, 48 and 72 hours after
tracer injection using a large field of view γ camera
(Orbiter, Siemens, Erlangen, Germany) with a high-
energy collimator and a 20% window centered at
364 Kev.
Fluorine-18 FDG PET
PET imaging was performed using a whole-body
PET EXACT 47 scanner (Siemens, Erlangen, Germany).
Patients were studied in fasting conditions for at least
4-6 hours before FDG injection. Patients were posi-
tioned on the PET gantry using a rectilinear scan com-
puterized program localized on the superior abdo-
men. Before injection of 18F FDG, abdomen transmis-
sion scan using a rod source of Ge-67 for the attenu-
ation correction of the corresponding emission scans
was performed for 20 minutes. Thereafter, patients
were intravenously injected with 370 MBq of 18F FDG.
Abdomen emission imaging was acquired between
30 and 45 minutes after FDG administration. Images
were reconstructed using filtered backprojection
smoothed with a Hann filter with a cutoff frequency
of 0.4 cycles/pixels by SUN Workstation System
(Siemens, Erlangen, Germany) generating three-
dimensional PET scans as axial, coronal and sagittal
views.
Data analysis
Adrenal function, either cortical and medullary,
was considered normal when the corresponding
hormone values were in the normal range. The ana-
tomic characteristics of adrenal tumours were
assessed on MR images; in particular, tumour size
was measured as maximal diameter in centimeters
and the characteristics of lesion margins (regular or
irregular) were assessed. Comparative evaluation of
MR and radionuclide imaging findings was focused
in adenomas, pheos and malignant adrenal lesions,
both primary tumours and metastases; the remaining
adrenal lesions, represented by cysts or myelolipo-
ma, were not considered for the comparative imag-
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ing analysis. The results of histology after surgery,
adrenal biopsy or 2-years clinical-imaging follow-
up were considered the standards of references; in
particular, this latter criterion was used in 11 cases of
non-hypersecreting cortical adenomas, ranging as
maximal diameter between 2.0 and 3.0 cm, which
were not surgically removed for the small tumor
size. 
MR images were evaluated using both qualitative
and quantitative analysis. Signal intensity of adrenal
lesions was qualitatively assessed on T2-weighted
images in terms of hypo-, iso- or hyperintensity com-
pared to that of liver tissue; furthermore, lesion
enhancement on T1-weighted images after gadolin-
ium administration (yes or no) as well as signal inten-
sity loss on out-phase CS images (yes or no) were also
analyzed, as previously described.4, 6 Signal intensity
of adrenal lesions was quantitatively assessed on T2-
weighted images as well as on T1-weighted images
after gadolinium in terms of signal intensity ratios
(SIRs) using region of interest analysis. SIRs consist-
ed of ratios between absolute signal intensity of
adrenal lesion and that of liver, fat and muscle tissues
as well as that of image background. This compara-
tive analysis was performed among adenomas, phe-
os and malignant adrenal tumors using the Student’s
“t” test for unpaired data. Data were expressed as
mean±1SD. Probability values <0.05 were consid-
ered significant.
Radionuclide studies were qualitatively evaluated
independently without knowledge of clinical and
pathologic findings. In particular, the presence of
TABLE I.—Qualitative MR and radionuclide imaging results of patient population.
# Lesion Site Size° MR T2* MR Gd^ MR CSI” nor-Chol MIBG FDG
1 Adenoma L 3.5 Hyperintense No Yes + — na
2 Adenoma L 3.0 Isointense No Yes + — na
3 Adenoma L 2.5 Isointense No Yes + — na
4 Adenoma R 6.0 Hyperintense Yes Yes + — na
5 Adenoma L 3.0 Hyperintense No Yes + na na
6 Adenoma R 2.5 Isointense No Yes + na na
7 Adenoma L 2.0 Hyperintense No Yes + na na
8 Adenoma L 2.5 Isointense No Yes + — na
9 Adenoma R 3.0 Hyperintense No Yes + na na
10 Adenoma L 3.0 Isointense No Yes + — —
11 Adenoma R 2.0 Hypointense No Yes + — —
12 Adenoma R 2.0 Hypointense No Yes + na na
13 Adenoma L 2.5 Hyperintense No Yes + na na
14 Pheochromocytoma L 5.0 Hyperintense Yes No - + na
15 Pheochromocytoma R 3.5 Hyperintense Yes No na + na
16 Pheochromocytoma L 2.5 Hyperintense Yes No na + na
17 Pheochromocytoma L 5.5 Hyperintense Yes No na + na
18 Carcinoma R 12.0 Hyperintense Yes No na — —
19 Carcinoma L 6.5 Hyperintense No No na na —
20 Carcinoma L 10.0 Hyperintense No No na — —
21 Carcinoma R 5.0 Hyperintense Yes No — na —
22 Sarcoma L 13.0 Hyperintense Yes No na na —
23 Lung metastasis L 2.0 Hyperintense No No — na —
24 Lung metastasis R 5.0 Hyperintense Yes No na na —
25 Melanoma metastasis R 4.5 Hyperintense Yes No na na —
26 Cyst L 5.5 Hyperintense No No na — na
27 Cyst L 5.0 Hyperintense No No — — na
28 Cyst L 5.0 Hyperintense No No — na na
29 Myelolipoma R 11.0 Hyperintense No Yes — na na
30 Myelolipoma R 4.0 Hyperintense No Yes — na —
°: maximal diameter in centimeters; *: lesion signal intensity compared to liver signal intensity; ^: enhancement after gadolinium administration; “: signal
intensity loss; nor-Chol: nor-cholesterol; MIBG: metaiodobenzylguanidine; FDG: fluorine-deoxy-glucose; L: left; R: right; +: increased tracer uptake by adre-
nal lesion (scan positive); —: no tracer uptake by adrenal lesion (scan negative); na: not available.
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abnormally increased uptake of nor-cholesterol,
MIBG or FDG was analyzed in the adrenal regions
when a tumour lesion was detected. The intensity of
tumour uptake was qualitatively evaluated on a high-
resolution display by 2 independent and experi-
enced nuclear medicine physicians. In case of dis-
agreement, final interpretation was determined by
consensus reading. Adrenal activity was considered
abnormal when tracer uptake was greater than initial
blood pool and surrounding background activity
and when no similar uptake was observed on the
contralateral side.
Results
In all patients, laboratory evaluation of both corti-
cal and medullary adrenal function, confirmed normal
levels of the corresponding hormones. The results of
qualitative MR imaging and radionuclide scans are
illustrated in Table I.
MR qualitative analysis
In patients with adrenal adenomas, the evaluation
of T2-weighted images demonstrated signal hyperin-
tensity in 46% of cases; no significant lesion enhance-
ment after gadolinium administration occurred in the
majority (92%) of these tumors (Figure 1); finally, sig-
nal intensity loss on out-phase CS images was
observed in all cases (100%), (Figure 2). In patients
with pheos, the evaluation of T2-weighted images
demonstrated signal hyperintensity in all cases (100%)
and similarly significant lesion enhancement occurred
after gadolinium administration in all cases (100%),
(Figure 3); no CS signal intensity change from in-
phase to out-phase imaging occurred in pheos. In
patients with adrenal malignant tumors, the evaluation
of T2-weighted images demonstrated signal hyperin-
tensity in all cases (100%); significant lesion enhance-
ment after gadolinium administration occurred in the
majority (63%) of these tumors. Signal intensity loss on
out-phase CS images in these tumours was not
observed.
MR quantitative analysis
The results of quantitative evaluation of SIRs on
T2-weighted MR images are reported in Table II; in
particular, signal hyperintensity of pheos was signif-
icantly higher compared to that of adenomas and
malignant tumors, while no differences were observed
between these latter adrenal lesions. The results of
quantitative evaluation of SIRs on T1-weighted MR
images performed after gadolinium administration
are reported in Table III; in particular, signal intensity
after gadolinium was significantly higher in pheos
compared to that of adenomas and malignant tumors,
Figure 1.—A 42-year-old woman with a small (2 cm) right adrenal adenoma. A) Abdominal T1-weighted axial MR imaging shows a right adren-
al mass with low signal intensity. B) Abdominal T1-weighted axial MR imaging after gadolinium administration shows no lesion enhance-
ment.
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while no differences were observed between differ-
ent types of adrenal tumours.
Radionuclide imaging
The results of qualitative evaluation of nuclear stud-
ies showed abnormally increased nor-cholesterol
uptake in 100% of cases with adenomas (Figure 4)
and, similarly, abnormal MIBG activity in 100% of
pheos (Figure 5) as well as increased FDG uptake in
100% of malignant adrenal tumors (Figure 6); in par-
ticular, no false positive or negative findings were
observed in all series of radionuclide studies. 
Discussion
The data on imaging of asymptomatic non-hyper-
secreting adrenal masses has recently increased since
the wide use of highly sensitive diagnostic techniques
such as CT and MRI for the evaluation of the abdomen.
In patients with these non-secreting tumours, the main
role of imaging is not just to identify the presence of
the tumour but to help characterise its type in a non-
invasive way. This will help to ensure appropriate
treatment. It is of particular importance to differentiate
between benign and malignant lesions. CT and MR
studies offer accurate anatomic details of any adren-
Figure 2.—A 37-year-old man with a small (2 cm) right adrenal adenoma. A) Abdominal T1 in-phase chemical-shift MR imaging shows
lesion low signal intensity. B) Abdominal T1 out-phase chemical-shift MR imaging clearly shows loss of lesion signal intensity compared to
in-phase acquisition.
Figure 3.—A 29-year-old man with a large (5.5 cm) left adrenal pheochromocytoma. A) Abdominal T1-weighted axial MR imaging shows a
left adrenal mass with low signal intensity. B) Abdominal T2-weighted axial MR imaging shows a left adrenal mass with high signal inten-
sity. C) Abdominal T1-weighted axial MR imaging after gadolinium administration shows significant, but inhomogeneous lesion enhancement.
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al tumour and will give an initial analysis of lesion
characterization.5, 6, 18, 19 In particular, adrenal adeno-
mas may be suggested by CT on the basis of low
attenuation coefficient on un-enhanced images and/or
early as well as rapid washout on enhanced scans.
Similarly, MR is able to characterize adenomas using
dynamic-gadolinium or chemical-shift sequences.
Pheos also show specific MR features such as clearly
increased signal intensity on T2-weighted images and
significant enhancement after gadolinium administra-
tion. Since gadolinium-enhanced MR imaging shows
a considerable overlap in the characteristics of benign
and malignant masses, its clinical applicability is lim-
ited in distinguishing adenomatous from non-ade-
nomatous adrenal lesions. Conversely, chemical-shift
acquisition using the basis of fat content of a lesion can
determine adenomas from malignant lesions. It is well
known that adenomas contain a large amount of
cytoplasmatic lipid in contrast to adrenal metastases
which contain little or none. In the majority of aden-
omas, the MR pattern seen consists of a reduction of
signal intensity on out-of-phase scan compared with
in-phase images, whereas in malignant lesions signal
intensity remains unchanged. However, some aden-
omas may contain insufficient lipid to result in loss of
signal on out-of-phase scan as well as malignant pri-
mary and secondary adrenal tumors may have lipid
component showing loss of signal intensity on chem-
ical-shift imaging and therefore this may reduce the
sensitivity of this technique. Despite the effective-
ness, this overlap in MRI appearances and tumour
type mean that there remains a need for complemen-
tary functional imaging.
Radionuclide modalities using specific tracers such
as nor-cholesterol, MIBG and FDG may provide in vivo
tissue characterization of adrenal tumours being able
TABLE II.—Quantitative analysis of T2-weighted MR images.
SIRs Adenoma Pheo Malignancies
Lesion/liver 1.9±1.0 3.4±1.0*° 2.7±0.8
Lesion/fat 0.75±0.3 1.7±0.5*° 1.1±0.5
Lesion/muscle 3.5±2. 7.8±3.5*° 4.1±2.2
Lesion/background 9.1±5.8 32±20*° 13±7.0
SIRs: signal intensity ratios; Pheo: pheochromocytoma; p<0.001 vs adenoma;
°p<0.03 vs malignancies.
TABLE III.—Quantitative analysis of T1-weighted gadolinium MR
images.
SIRs Adenoma Pheo Malignancies
Lesion/liver 1.0±0.25 1.4±0.28*° 1.0±0.2
Lesion/fat 0.62±0.16 0.92±0.21*° 0.5±0.1
Lesion/muscle 2.0±0.5 2.6±0.35*° 1.8±0.6
Lesion/background 16±12 35±31*° 23±13
SIRs: signal intensity ratios; Pheo: pheochromocytoma; p<0.001 vs adenoma;
°p<0.03 vs malignancies.
Figure 4.—A 22-year-old woman with a 2.5 cm right adrenal adenoma. A) Abdominal T1-weighted axial MR imaging after gadolinium admin-
istration shows a right adrenal mass. B) Abdominal posterior view of iodine-131 nor-cholesterol delayed imaging shows a round area of increased
and exclusive tracer uptake in the right adrenal bed corresponding to the mass; no activity was observed in the contralateral side.
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to differentiate between benign and malignant abnor-
malities. Since these agents have no relation to each
other and are taken up by individual parts of adren-
als on the basis of entirely separate mechanism, they
are able to differentiate different types of tumours.7, 12-
15 In particular, radiolabeled nor-cholesterol scintigra-
phy allows the characterization of functioning, but
not hypersecretory, benign cortical adenomas; similar-
ly, MIBG imaging has been demonstrated to be use-
ful to identify non-hypersecreting pheos 20, 21 and flu-
oro-18 FDG using PET scanning has been shown to
be able to recognize malignant adrenal tumours on the
basis of increased glucose metabolism.13-15
In the present study, we compared the results of MR
techniques and those of radionuclide studies in a
group of patients with non-hypersecreting adrenal
masses in order to evaluate imaging criteria for accu-
rately performing tumour characterization. On the
Figure 5.—A 32-year-old man with a 3 cm right adrenal pheochromocytoma. A) Abdominal T1-weighted axial MR scan shows a round right
adrenal mass. B) Abdominal posterior view of MIBG imaging shows a round area of intense and exclusive tracer uptake in the right adren-
al bed; no activity was observed in the contralateral side.
Figure 6.—A 44-year-old woman with a 4.5 cm right adrenal metastasis by melanoma. A) Abdominal T1-weighted axial MR scan shows a large
right adrenal mass. B) Uncorrected abdominal FDG PET scan shows intense tracer uptake by the right adrenal lesion; diffuse physiologic activ-
ity is detectable in the liver and normal focal uptake is present in the upper pole of the right kidney as well as in the left kidney.
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basis of our analysis, MR qualitative patterns to iden-
tify adrenal adenomas consisted of no lesion enhance-
ment after gadolinium or, mainly, signal intensity loss
on out-phase CS imaging; this latter criterion is more
appropriate since no gadolinium enhancement occurs
also in other benign adrenal tumours.6, 18, 22 Conversely,
the comparative evaluation of T1-T2 signal intensity
changes demonstrated in our experience inhomoge-
neous findings not allowing definite adenoma charac-
terization since on T2 images 54% of these lesions
were hypo- or iso-intense and the other 46% showed
hyperintensity. For pheos, T2 signal hyperintensity
and significant gadolinium enhancement were char-
acteristicly occurring in all cases; likewise, in adren-
al malignancies signal hyperintensity was found in
all cases, while gadolinium enhancement occurred
only in 63% of these tumours. These observations
suggest that T2 signal hyperintensity is not accurate in
differentiating adrenal masses, as previously reported
by our group.22 Since CS is not able to identify phe-
os or adrenal malignancies, other methodological
approaches may be needed. For this purpose, the
results of MR quantitative analysis showed that the
degree of T2 signal hyperintensity and of lesion
enhancement after gadolinium were significantly high-
er in pheos compared to those of adenomas and
malignant tumours but these latter lesions were not
distinguished according to these quantitative criteria.
These findings confirm the data of previous investiga-
tions 4, 6, 7 suggesting that, although the availability of
several technical methods, MR imaging provide only
some presumptive criteria for tissue characterization
in patients with non-hypersecreting adrenal masses.
In particular, signal intensity loss on out-phase CS
sequence seems to be the best marker for adenomas
and the quantitative assessment of T2 or T1-gadolin-
ium signal intensity allows to better characterize phe-
os, while no specific MR criteria for adrenal malig-
nancies are available.
In our series, the results of radionuclide studies
were more homogeneous compared to those of MR
imaging in terms of adrenal tumour characterization
selectively showing nor-cholesterol uptake in adeno-
mas, increased MIBG activity in pheo and abnormal
FDG accumulation in, both primary and metastatic,
adrenal malignancies. Although only a limited group
of radionuclide scans were available, the 3 different
radiotracers we used were able to identify different
types of adrenal masses. In fact, nor-cholesterol uptake
occurred in 100% of adenomas, MIBG concentration
was found in 100% of pheo, FDG accumulation was
observed in 100% of malignancies, with no collec-
tion of false negative or positive results. Therefore,
according to our experience 10, 15, 23 and that of others,7,
13, 14, 21 radionuclide imaging using specific radiocom-
pounds offers specific non-invasive tissue character-
ization in patients with non-hypersecreting adrenal
masses. In this regard, the selection of the appropri-
ate radioagent to be used depends on the clinical
patient history but it may be limited if appropriate
radiopharmaceuticals and nuclear equipment are not
available. Because benign adenomas are the most
common cause of non-hypersecreting adrenal tumors,
labeled nor-cholesterol should be the 1st choice for
patients with no history of cancer disease. In case of
a normal nor-cholesterol scan, MIBG should be used
to confirm or rule out the presence of non-hyperse-
creting pheo. If MIBG is also normal, FDG PET may
be considered when the clinical suspicion of malignan-
cy is high. Conversely, when neoplastic patients are
evaluated, FDG PET should be initially performed
followed, if normal, by nor-cholesterol and, in
sequence, MIBG studies.
Nuclear studies are not routinely used in the diag-
nostic protocols for managing patients with non-
hypersecreting adrenal masses as well as are infre-
quently considered for clinical decision making in
such field.24, 25 Although combinations of anatomic
criteria by CT and MR are currently used to identify
malignancy or benignancy without resorting to radio-
nuclide imaging studies, on the basis of recent expe-
riences a diagnostic role of molecular imaging has
been proposed in this setting which may effect patient
management.9 In fact, a radionuclide diagnosis of
non-hypersecreting adenoma by nor-cholesterol
requests surgical treatment only if large tumour size
occurs, otherwise clinical and imaging follow-up is
appropriate; similarly, nuclear characterization of phe-
ochromocytoma by MIBG allows to correctly plan
surgery with adequate patient preparation, and, final-
ly, early identification of adrenal malignancy by FDG
PET may determine timely tumour resection with pos-
sible favourable patient prognosis.
Conclusions
In conclusion, in patients with non-hypersecreting
adrenal masses MR imaging may provide some pre-
sumptive criteria to characterize tumour lesions; no
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gadolinium enhancement and definite signal intensity
loss on CSI suggest adenomas, while quantitatively
measured T2-hyperintensity and/or gadolinium
enhancement are able to identify pheos. Conversely,
radionuclide techniques offer more specific findings
since nor-cholesterol and MIBG uptake occur only in
benign lesions such adenoma and pheos, respective-
ly, and FDG accumulation detects adrenal malignancies.
Therefore, multi-agents adrenal scintigraphy is strong-
ly recommended in the diagnostic protocol of patients
with non-hypersecreting adrenal masses, particularly
when MR findings are uncertain and inconclusive.
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